ARQL ArQule Inc.

9.68
0  0%
Previous Close 9.68
Open
Price To Book 14.89
Market Cap 1,058,119,609
Shares 109,309,877
Volume 45,631
Short Ratio
Av. Daily Volume 3,047,393

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 registrational MOSAIC trial to be initiated 3Q 2019.
ARQ 092
Overgrowth Diseases
Phase 1/2 trial ongoing.
Derazantinib (ARQ 087)
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer
Phase 1b data due 2H 2019.
Miransertib - ARQ 092
Solid tumors
Phase 1 data at EHA June 14, 2019 noted 66% (4/6) ORR in CLL patients.
ARQ 531
B-cell malignancies
Phase 1b data to be presented 2H 2019.
ARQ 751
Solid tumors
Phase 1/2 trial to be initiated mid-2019.
Derazantinib (BAL087) and Atezolizumab (Tecentriq)
Urothelial cancer

Latest News

  1. ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019
  2. The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
  3. Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal
  4. ArQule Hits 12-Year High Following Favorable Midstage Study Results
  5. 2 Rallying Pharma Stocks Roping In Option Bulls
  6. Here's Why ArQule Is Soaring Again Today
  7. Company News For Jun 17, 2019
  8. ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference
  9. The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
  10. ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results
  11. A Look At Benzinga Pro's Most-Searched Tickers For June 14
  12. Here's Why ArQule Shares Rose as Much as 44.7% Today
  13. ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results
  14. Why Small-Cap Biotech ArQule Is Rallying
  15. Stock Market News: Chewy Goes Public; ArQule Soars on Cancer Study
  16. ArQule stock rockets 49% toward 12-year high after biotech announces Phase 1 trial results
  17. The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
  18. ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting
  19. Imagine Holding ArQule (NASDAQ:ARQL) Shares While The Price Zoomed 346% Higher
  20. ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference